Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
This dermatology-focused biotech, known for its topical therapies, reported a notable insider sale amid strong one-year stock gains.
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
Overview
Sue-Jean Lin, a director of Arcutis Biotherapeutics (NASDAQ:ARQT), reported the sale of 4,946 shares of common stock on June 15, 2026, as disclosed in this SEC Form 4 filing.
Transaction value based on SEC Form 4 reported price ($24.38); post-transaction value based on SEC Form 4 reported share count and the derived total value ($705,163.86).
Details
* 1-year price change calculated using June 15, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
